Lucid Diagnostics Partners With VITALExam, To Enhance Access To Lucid's EsoGuard Esophageal DNA Test For Firefighters At Risk For Esophageal Precancer

Benzinga12/19 21:17

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication

PR Newswire12/11 21:01

PAVmed Is Maintained at Buy by Ascendiant Capital

Dow Jones12/09 17:35

PAVmed Analyst Ratings

Benzinga12/09 17:22

Press Release: Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Dow Jones12/03 21:01

PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.

Benzinga11/20 21:38